article thumbnail

XtalPi and CK Life Sciences to develop AI-driven tumour vaccine R&D platform

Pharmaceutical Technology

XtalPi has entered a strategic partnership with CK Life Sciences for artificial intelligence (AI)-driven tumour vaccine research and development (R&D). Under the collaboration, the companies will utilise their capabilities to co-develop a new AI tumour vaccine R&D platform.

article thumbnail

Forbion raises $1.47bn for two life sciences-focused funds

Pharmaceutical Technology

European life sciences venture capital firm Forbion has raised €1.35bn ($1.47bn) across its two new funds. The Forbion Ventures Fund VI is focused on developing a portfolio of therapeutics companies, including existing biotechs and new companies.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Indian life sciences sector integrating technologies in R&D efforts

AuroBlog - Aurous Healthcare Clinical Trials blog

The Indian life sciences sector is making strides by integrating quantum computing, artificial intelligence (AI), machine learning (ML), advanced analytics, big data, internet of things (IoT) and blockchain into their research and development efforts.

article thumbnail

Industry calls for boosting innovation and investment in NCEs and NBEs to propel life sciences growth

AuroBlog - Aurous Healthcare Clinical Trials blog

As the Union Budget approaches, the life sciences sector anticipates substantial support to enhance innovation and investment in the development of new chemical entities (NCEs) and new biological entities (NBEs). The life sciences sector in India has shown remarkable resilience […]

article thumbnail

Tiziana Life Sciences plans to assess intranasal foralumab for long Covid

Pharmaceutical Technology

Biotechnology company Tiziana Life Sciences has revealed plans to assess intranasal foralumab as a potential treatment for long Covid. Long Covid is a health condition characterised by the continuation or development of new symptoms three months after an initial SARS-CoV-2 infection.

article thumbnail

GSK and Wave Life Sciences partner to develop oligonucleotide therapeutics

Pharmaceutical Technology

GSK has entered a strategic partnership with Wave Life Sciences to progress the discovery and development of oligonucleotide therapies for new genetic targets. The discovery alliance, with a preliminary research period of four years, will aid GSK in progressing up to eight programmes and Wave to develop up to three programmes.

article thumbnail

RESCAP by Alloksys Life Sciences for Burns: Likelihood of Approval

Pharmaceutical Technology

RESCAP is under clinical development by Alloksys Life Sciences and currently in Phase II for Burns.